Skip to main content
Caplight Logo









Mediar Therapeutics

Mediar Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.mediartx.com/

Last Round

Series B

Jan 7, 2026

Est. Valuation

$230.3M

Total Funding Raised

$181M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Mediar Therapeutics is a biotechnology company developing innovative antibody-based therapies aimed at halting and reversing fibrotic activity in chronic organ damage.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

fibrosisbiotechnologytherapeutic antibodyclinical-stage pipelinesystemic sclerosischronic kidney diseaseCKDdrug discoverybiotech startupclinical trialsfirst-in-class therapybiopharma partnershipfibrotic diseasedrug developmentbiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mediar Therapeutics Comparables

Compare Mediar Therapeutics with similar companies based on industry and business-model similarity.

Mediar Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Endeavor BioMedicines
81%
Certa Therapeutics
81%
AgomAb Therapeutics
80%

Mediar Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJan 7, 2026
Series AMar 15, 2023
SeedMar 17, 2021

Mediar Therapeutics Investors

Notable investors and investment history

Mediar Therapeutics investors
InvestorRounds
Agent CapitalSeed
GimvSeries B, Series A
Asahi Kasei Pharma VenturesSeries B
Amplitude VenturesSeries B
Mass General Brigham InnovationSeries A, Seed
Intermediate Capital GroupSeries B
Viva BiotechSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors increased 108% MoM, reaching 4.3K.

  • Jan 7, 2026

    $76M round completed.

Mediar Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Mediar Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mediar Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range56
Year Founded2018
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?